Core Insights - CDT Equity Inc. announced the acquisition of 9.25648743 Bitcoin for a total price of $1,005,000, averaging $108,301.75 per BTC, increasing total holdings to 17.9090111 BTC [1][2] Group 1: Acquisition Details - The acquisition is part of CDT's cryptocurrency treasury reserve strategy aimed at diversifying the balance sheet and enhancing long-term shareholder value through digital asset accumulation [2][3] - The total Bitcoin holdings of CDT now amount to 17.9090111 BTC following this transaction [1] Group 2: Strategic Intent - CDT's CFO emphasized a disciplined and opportunistic approach to capital management, aligning with the growing institutional adoption of digital assets and aiming to strengthen financial resilience [3] - The company is committed to strategically deploying capital within its treasury reserve program, focusing initially on Bitcoin [3] Group 3: Company Overview - CDT Equity Inc. is a biopharmaceutical development company that leverages scientific innovation and strategic partnerships to advance therapeutic assets [3] - The company has evolved from Conduit Pharmaceuticals to a broader platform utilizing artificial intelligence and efficient asset repositioning for novel treatment development [3]

Core Insights - CDT Equity Inc. has announced the acquisition of 8.65252366 Bitcoin for a total cost of $1,000,000, averaging $115,285 per Bitcoin [1][2]. Group 1: Strategic Acquisition - The acquisition of Bitcoin is part of CDT's treasury reserve strategy aimed at enhancing financial stability and resilience of the balance sheet [2][3]. - This move aligns with the growing institutional adoption of digital assets in a regulatory environment that is becoming more favorable [2]. Group 2: Management Commentary - James Bligh, CFO of CDT, expressed satisfaction with the execution of this strategy, emphasizing its role in diversifying the balance sheet and supporting an innovation-driven business model [3]. - The company is committed to continuously evaluating asset allocation to optimize its treasury portfolio and enhance shareholder returns [3].

Core Insights - Eyenovia has acquired a significant position in HYPE tokens, making it the first Nasdaq-listed company to operate a validator on the Hyperliquid blockchain [1][2] - The company has successfully closed a $50 million private placement (PIPE) to fund the acquisition of 1,040,584.5 HYPE tokens at an average price of approximately $34 per token [2][3] - Eyenovia is on track for FDA registration of its Optejet User Filled Device (UFD) by September 2025, with ongoing discussions for potential partnerships [1][5] Company Strategy - The acquisition of HYPE tokens is part of Eyenovia's new cryptocurrency treasury reserve strategy aimed at creating long-term shareholder value through digital currency adoption [3] - The company plans to initiate its own network validator to support the Hyperliquid blockchain and access HYPE staking yield [2][3] - Eyenovia is expected to change its name and ticker to "Hyperion DeFi" and "HYPD" pending Board approval [4] Product Development - Development of the Optejet UFD is progressing as planned, with verification and validation activities set to begin next month [5] - The Optejet is designed for various topical ophthalmic liquids, enhancing treatment compliance and outcomes for patients with chronic front-of-the-eye diseases [9] Hyperliquid Platform Overview - Hyperliquid is a layer one blockchain optimized for high-frequency trading, featuring on-chain perpetual futures and spot order books [6] - HYPE, the native token of Hyperliquid, provides utility through reduced trading fees and increased referral bonuses, with over 25 million HYPE sequestered by the blockchain as of June 2025 [7]